TOOL DEVELOPMENT FOR MEASURING AVARANA (OCCLUSION OF BODY CHANNELS) AND ASSESSMENT OF THE EFFECT OF SELECTED AYURVEDIC ANTIAVARANA DRUGS, IN METABOLIC SYNDROME

DEVELOPMENT AND VALIDATION OF A TOOL FOR MEASURING AVARANA (OCCLUSION OF BODY CHANNELS) AND ASSESSMENT OF THE EFFECT OF SELECTED AYURVEDIC ANTIAVARANA DRUGS, IN METABOLIC SYNDROME

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/013837

Enrollment

220

Registered

2018-05-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Participants with and without Metabolic syndrome

Interventions

Intervention1: Tool development: Descriptive, Cross sectional study Intervention2: Drug: Powder of Tinospora cordifolia(Guloochi) and Commiphora mukul(Guggulu), 6g twice daily, orally, for 60 days Con

Eligibility

Inclusion criteria

Inclusion criteria: The subjects with the age group of 30-70years with and without Metabolic syndrome were included in the study. Those who were ready to give consent, for the administration of the draft tool were only included in phase 1.In phase 2, the diagnosed cases of metabolic syndrome with newly developed Avarana tool (AMT-MS) score above 22 were included.

Exclusion criteria

Exclusion criteria: Patients with other major systemic diseases and the patients who were not co-operating with the study were excluded in both phases

Design outcomes

Primary

Measure	Time frame
Measurement tool for Avarana in Metabolic syndromeTimepoint: At the time of evaluation	—

Secondary

Measure	Time frame
Effect of selected Ayurvedic Antiavarana drugs in Avarana score in metabolic syndromeTimepoint: 1st, 30th, 60th and 90th	—

Countries

India

Contacts

Public ContactDr MAShajahan

Govt. Ayurveda College, Thiruvananthapuram.

drpriya73@gmail.com9447694713

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026